IGF::OT::IGF PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN AND SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF BIOMARKER AND MITOCHONDRIAL TOXICITY ASSAYS.
IGF::OT::IGF PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN AND SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF BIOMARKER AND MITOCHONDRIAL TOXICITY ASSAYS.
批准号:
9362026
负责人:
JON MIRSALIS
金额:
$200.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-03-14 至 2017-03-13
关键词:
Acquired Immunodeficiency SyndromeAmikacinAnimalsBinding ProteinsBiologicalBiological AssayBiological AvailabilityCanis familiarisCardiovascular systemContractsDevelopmentDevelopment PlansDoseDrug InteractionsDrug KineticsExcretory functionFecesFormulationG protein coupled receptor kinaseGenitourinary systemHIVHIV InfectionsImmunologicsIn VitroInterventionLiquid substanceMetabolismMitochondriaModelingMusNational Institute of Allergy and Infectious DiseaseNeuraxisNo-Observed-Adverse-Effect LevelPharmacodynamicsPharmacologic SubstancePharmacologyPharmacology and ToxicologyPlasmaPlasma ProteinsProteomicsRattusReference StandardsResearch PersonnelSafetySamplingServicesSystemTestingTherapeutic AgentsTherapeutic EquivalencyTissuesToxic effectToxicogenomicsToxicologyUnited States Dept. of Health and Human ServicesUnited States National Institutes of HealthUrineabsorptionbiomarker developmentcarcinogenicityclinical investigationco-infectiondrug developmentgastrointestinalgenotoxicityimmunotoxicityin vivometabolomicsmicrobicidenonhuman primatepreventreproductive toxicityrespiratorysexual HIV transmissiontransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Division of Acquired Immunodeficiency Syndromes (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), maintains a portfolio of contracts to support the development of (1) therapies for HIV infection and its complications and coinfections, and (2) microbicides for preventing the sexual transmission of HIV. Services provided under this contracts assist investigators in academic settings and small pharmaceutical firms in filling specific gaps in their drug development plan as they advance their product towards clinical investigation of therapies for HIV infection and interventions to prevent HIV transmission. Activities will include the development of formulations of potential therapeutic agents and microbicides. In addition studies will be conducted to assess the pharmacology and toxicology of potential therapeutic agents and microbicides.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Task Order D14: Preclinical, Microbiological, Safety, Toxicology, and Pharmacokinetic Services
-
批准号:10901158
-
项目类别:
-
资助金额:$475.03万
-
财政年份:2023
-
负责人:JON MIRSALIS
-
依托单位:
Task C19: Recertification for clinical use of GMP Product
-
批准号:10683807
-
项目类别:
-
资助金额:$15.77万
-
财政年份:2022
-
负责人:JON MIRSALIS
-
依托单位:
TASK A06: DEVELOPMENT OF A PRECLINICAL NEPHROTOXICITY SCREENING PLAN
-
批准号:10613209
-
项目类别:
-
资助金额:$4.98万
-
财政年份:2022
-
负责人:JON MIRSALIS
-
依托单位:
Task C15: APP SYNTHESIS OF YELLOW FEVER COMPOUNDS
-
批准号:10613201
-
项目类别:
-
资助金额:$12.24万
-
财政年份:2022
-
负责人:JON MIRSALIS
-
依托单位:
Task Order D-13 PRE-CLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES
-
批准号:10895064
-
项目类别:
-
资助金额:$227.2万
-
财政年份:2022
-
负责人:JON MIRSALIS
-
依托单位:
Task A03: Nonclinical Service Training
-
批准号:10448654
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
Task B19: Synthesis of LpxC Inhibitors with Improved Physicochemical Properties
-
批准号:10382938
-
项目类别:
-
资助金额:$25.71万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
TISSUE CROSS-REACTIVITY STUDY OF A HUMAN ANTIBODY
-
批准号:10474740
-
项目类别:
-
资助金额:$10.75万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
Task A5: Update of Generic Product Development Plan
-
批准号:10454571
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting
-
批准号:10397446
-
项目类别:
-
资助金额:$2.94万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
Task A03: Nonclinical Service Training
-
批准号:10579805
-
项目类别:
-
资助金额:$3.21万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
TASK C12: INVESTIGATION AND OPTIMIZATION OF PRECLINICAL THERAPEUTIC FORMULATIONS AGAINST RESISTANT BACTERIA
-
批准号:10393342
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2021
-
负责人:JON MIRSALIS
-
依托单位:
Task C08: Manufacturing of a colon-delivery formulation platform of metronidazole for treating Clostridium difficile infection
-
批准号:10254515
-
项目类别:
-
资助金额:$157.54万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials
-
批准号:10449189
-
项目类别:
-
资助金额:$29.48万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services
-
批准号:10414864
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Task D05: Nonclinical Services for the Development of Interventional Agents for Infectious Diseases
-
批准号:10246566
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Task C08: Manufacturing of a colon-delivery formulation platform of metronidazole for treating Clostridium difficile infection
-
批准号:10361172
-
项目类别:
-
资助金额:$11.51万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Task B11: Polymorph characterization and salt screening of a potential therapeutic for gram negative bacteria
-
批准号:10115304
-
项目类别:
-
资助金额:$4.02万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials
-
批准号:10215314
-
项目类别:
-
资助金额:$78.56万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services
-
批准号:10414863
-
项目类别:
-
资助金额:$12.73万
-
财政年份:2020
-
负责人:JON MIRSALIS
-
依托单位:
海外基金